Latest News about NVS
Recent news which mentions NVS
From Benzinga
From Benzinga
3 No-Brainer Stocks to Buy With $1,000 Right Now
March 14, 2022
From Motley Fool
From Benzinga
NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting
March 10, 2022
Tickers
NVS
From Benzinga
7 Drug Stocks To Consider After the Viatris Plunge
March 10, 2022
From InvestorPlace
From Benzinga
Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs
March 08, 2022
From Benzinga
Pharmaceutical Companies Are Reportedly Refocusing On Mysterious Rise In Shingles Infections As COVID Declines
March 07, 2022
From Benzinga
Viatris Just Snagged a Major FDA Approval
March 03, 2022
From Motley Fool
Consumer Spending, E-Commerce, and the Business of Lodging
March 02, 2022
From Motley Fool
From Benzinga
This Biotech Company Reports Making Ground-Breaking Strides In Combating Solid Tumors
February 23, 2022
From Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
From Benzinga
From Benzinga
New FDA program could boost drug development for rare diseases
February 15, 2022
From MarketWatch
3 High-Yield Dividend Stocks to Buy and Hold for Decades
February 12, 2022
From Motley Fool
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
February 10, 2022
From Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
From Benzinga
Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19
February 10, 2022
From Benzinga
Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?
February 03, 2022
From Benzinga
From Benzinga
Why Are Pharming Shares Trading Higher Today?
February 02, 2022
From Benzinga
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
February 02, 2022
From Benzinga
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
February 02, 2022
From Benzinga
Earnings Scheduled For February 2, 2022
February 02, 2022
From Benzinga
Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report
February 01, 2022
Tickers
NVS
From Benzinga
Is AbbVie Stock a Buy Now?
February 01, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.